Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Alexion Pharmaceuticals Inc's Business Segments
Alexion Pharmaceuticals Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q1 FY2021
Reportable Segments
5
Largest Segment
Soliris
Total Revenue
$ 1,637
Regions Reported
-
Revenue Share by Reportable Segment - Q1 FY2021
- Soliris62.8%
- Ultomiris21.2%
- Strensiq Product Line12.1%
- Kanuma Product Line2.1%
- Andexxa Product Line1.8%
Revenue by Reportable Segment - Q1 FY2021
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Soliris | $ 1,028 | 62.8% |
| Ultomiris | $ 347 | 21.2% |
| Strensiq Product Line | $ 198 | 12.1% |
2 more segments available
Sign in to unlock the full Alexion Pharmaceuticals Inc dataset.
Revenue by Product & Service Category - Q1 FY2021
- Product100%
- Net Product Sales100%
- Other Revenue0%
Revenue by Product & Service Category - Q1 FY2021
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 1,636 | 100% |
| Net Product Sales | $ 1,636 | 100% |
| Other Revenue | $ 1 | 0% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Alexion Pharmaceuticals Inc
Business Description: Alexion Pharmaceuticals Inc.
Overview:
Alexion Pharmaceuticals Inc. is a biopharmaceutical company dedicated to addressing the needs of patients with severe and ultra-rare disorders. Through innovation, research, and the development of life-altering therapies, Alexion has positioned itself as a leader in the field of complement-mediated diseases. The company is recognized for its commitment to transforming the lives of patients who suffer from debilitating health conditions that often lack effective treatment options.
Core Focus and Products:
The company’s flagship product, Soliris® (eculizumab), is the first and only approved therapy for two severe, ultra-rare disorders stemming from chronic uncontrolled activation of the complement system: paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). PNH is a rare genetic blood disorder that can lead to significant morbidity and mortality, while aHUS is characterized by hemolytic anemia, acute kidney injury, and thrombocytopenia.
Since its commercial launch in 2007, Soliris has been pivotal in improving outcomes for patients. The drugs mechanism targets the C5 complement component, inhibiting its activation and thereby controlling the harmful effects of the complement system in patients with these conditions. Alexion is actively exploring additional indications for Soliris in other severe and ultra-rare diseases linked to complement dysregulation.
In addition to Soliris, Alexion is advancing a robust pipeline of biotechnology product candidates designed for the treatment of severe and ultra-rare disorders. The company is committed to ongoing research and development efforts that focus on complement-mediated conditions, rare autoimmune disorders, and other related pathologies. Alexions dedication to innovation in therapeutics positions it strongly in the biopharmaceutical landscape.
Business Model:
Alexion Pharmaceuticals operates with a focused business model aimed at niche markets where competition is limited, and patient populations are small. This strategic orientation enables the company to address the unique medical needs of patients with complex and often life-threatening conditions. By prioritizing research and development, Alexion seeks to discover new treatment options that align with its mission to enhance the quality of life for patients impacted by severe and ultra-rare diseases.
Company History:
Founded in 1992, Alexion has evolved significantly, driven by a commitment to advancing therapies for patients facing severe health challenges. The successful commercialization of Soliris marked a pivotal moment in the company’s history, establishing it as a trusted partner in the treatment of ultra-rare disorders. Over the years, Alexion has expanded its reach through strategic collaborations, acquisitions, and investments in research to further promote its portfolio of innovative therapies.
Commitment to Patients:
At the core of Alexions business philosophy is a dedication to patients. The company prioritizes patient engagement and advocacy, ensuring that the voices of those it serves inform its research and development initiatives. By fostering partnerships with patient communities, healthcare professionals, and researchers, Alexion actively seeks to raise awareness and deliver effective solutions for patients grappling with life-altering health conditions.
Conclusion:
Alexion Pharmaceuticals Inc. stands as a prominent entity in the biopharmaceutical industry with an unwavering focus on severe and ultra-rare disorders. Through its pioneering work with Soliris and a promising pipeline of therapeutic candidates, the company is dedicated to transforming the lives of patients and advancing the field of medicine through innovative research and compassionate patient care.
Overview:
Alexion Pharmaceuticals Inc. is a biopharmaceutical company dedicated to addressing the needs of patients with severe and ultra-rare disorders. Through innovation, research, and the development of life-altering therapies, Alexion has positioned itself as a leader in the field of complement-mediated diseases. The company is recognized for its commitment to transforming the lives of patients who suffer from debilitating health conditions that often lack effective treatment options.
Core Focus and Products:
The company’s flagship product, Soliris® (eculizumab), is the first and only approved therapy for two severe, ultra-rare disorders stemming from chronic uncontrolled activation of the complement system: paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). PNH is a rare genetic blood disorder that can lead to significant morbidity and mortality, while aHUS is characterized by hemolytic anemia, acute kidney injury, and thrombocytopenia.
Since its commercial launch in 2007, Soliris has been pivotal in improving outcomes for patients. The drugs mechanism targets the C5 complement component, inhibiting its activation and thereby controlling the harmful effects of the complement system in patients with these conditions. Alexion is actively exploring additional indications for Soliris in other severe and ultra-rare diseases linked to complement dysregulation.
In addition to Soliris, Alexion is advancing a robust pipeline of biotechnology product candidates designed for the treatment of severe and ultra-rare disorders. The company is committed to ongoing research and development efforts that focus on complement-mediated conditions, rare autoimmune disorders, and other related pathologies. Alexions dedication to innovation in therapeutics positions it strongly in the biopharmaceutical landscape.
Business Model:
Alexion Pharmaceuticals operates with a focused business model aimed at niche markets where competition is limited, and patient populations are small. This strategic orientation enables the company to address the unique medical needs of patients with complex and often life-threatening conditions. By prioritizing research and development, Alexion seeks to discover new treatment options that align with its mission to enhance the quality of life for patients impacted by severe and ultra-rare diseases.
Company History:
Founded in 1992, Alexion has evolved significantly, driven by a commitment to advancing therapies for patients facing severe health challenges. The successful commercialization of Soliris marked a pivotal moment in the company’s history, establishing it as a trusted partner in the treatment of ultra-rare disorders. Over the years, Alexion has expanded its reach through strategic collaborations, acquisitions, and investments in research to further promote its portfolio of innovative therapies.
Commitment to Patients:
At the core of Alexions business philosophy is a dedication to patients. The company prioritizes patient engagement and advocacy, ensuring that the voices of those it serves inform its research and development initiatives. By fostering partnerships with patient communities, healthcare professionals, and researchers, Alexion actively seeks to raise awareness and deliver effective solutions for patients grappling with life-altering health conditions.
Conclusion:
Alexion Pharmaceuticals Inc. stands as a prominent entity in the biopharmaceutical industry with an unwavering focus on severe and ultra-rare disorders. Through its pioneering work with Soliris and a promising pipeline of therapeutic candidates, the company is dedicated to transforming the lives of patients and advancing the field of medicine through innovative research and compassionate patient care.
Alexion Pharmaceuticals Inc.: Comprehensive Overview of Segments, Products, and Services
Alexion Pharmaceuticals Inc. is a global biopharmaceutical company that focuses on developing and delivering innovative therapies for patients experiencing severe and ultra-rare disorders. Operating as a singular business segment, Alexion centers its efforts on providing specialized solutions tailored to meet the complex healthcare needs of this specific population. This targeted strategy streamlines decision-making, optimizes resource allocation, and fosters cross-functional collaboration across various operational pillars. Below is a detailed examination of the various segments, products, and services offered by Alexion Pharmaceuticals.
Business Segment Overview
Alexions strategic focus on the innovation, development, and commercialization of therapies allows it to operate without diversifying into less specialized areas. This concentrated operational model is designed to create a patient-first approach that prioritizes the unique and complex needs of individuals with severe illnesses. By concentrating its resources on specific diseases, Alexion enhances its ability to address unmet medical needs effectively.
Therapeutic Areas
Alexion Pharmaceuticals primarily concentrates its research and development activities in the following key therapeutic areas:
1. Hematology: This segment addresses a variety of blood disorders. Notable conditions include:
- Paroxysmal Nocturnal Hemoglobinuria (PNH): A rare and life-threatening blood disorder characterized by the destruction of red blood cells, leading to severe anemia.
- Complement-mediated Hemolytic Anemias: Conditions where the bodys immune system destroys red blood cells.
2. Neurology: Alexion is committed to addressing life-altering neurological disorders. A primary focus is:
- Neuromyelitis Optica Spectrum Disorder (NMOSD): An autoimmune condition that causes inflammation of the spinal cord and optic nerve.
3. Immunology: This area focuses on developing treatments that modulate the immune response, specifically for:
- Autoimmune Disorders: Conditions where the immune system erroneously attacks healthy cells.
4. Rare Genetic Diseases: Alexion targets various genetic disorders that require specialized treatment, often caused by mutations that severely impact health, including:
- Genetic metabolic disorders and other inherited conditions.
Key Products
Alexion Pharmaceuticals boasts a product portfolio largely characterized by monoclonal antibodies and complement inhibitors. Notable products include:
1. Soliris (eculizumab):
- This was the first drug approved for the inhibition of the complement protein C5. It is pivotal in treating PNH and atypical hemolytic uremic syndrome (aHUS), preventing complement-mediated damage to red blood cells and important organs.
2. Ultomiris (ravulizumab-cwvz):
- An innovative, longer-acting C5 inhibitor that provides treatment for PNH and aHUS with the advantage of requiring less frequent dosing compared to Soliris. Its pharmacokinetic profile offers enhanced patient convenience.
3. Strensiq (asfotase alfa):
- This enzyme replacement therapy is targeted at patients with hypophosphatasia, a rare genetic disorder that affects bone metabolism by providing the essential alkaline phosphatase enzyme that is lacking in these patients.
4. Kanuma (sebelipase alfa):
- Indicated for lysosomal acid lipase deficiency (LAL-D), this replacement therapy mitigates the severe health impacts associated with this genetic disorder.
Research and Development
Alexion Pharmaceuticals prioritizes extensive research and development efforts:
- Innovation: The company is heavily invested in discovering groundbreaking therapies for ultra-rare diseases, often targeting areas with minimal existing treatment options.
- Clinical Trials: Alexion conducts rigorous clinical trials that evaluate the safety and efficacy of its investigational therapies. These trials often involve collaborations with a global network of healthcare professionals, patients, and academic institutions.
- Pipeline Development: The company maintains a robust pipeline of investigational drugs aimed at meeting the needs of patients with severe and ultra-rare disorders, particularly focusing on complement inhibition and genetic conditions.
Patient-Centric Services
Alexion Pharmaceuticals features a suite of patient-centered services designed to support individuals receiving its therapies:
1. Patient Support Programs: These initiatives facilitate patient navigation through treatment protocols, providing essential educational resources alongside emotional and psychological support.
2. Access Solutions: Alexion implements various strategies to enhance patient access to its medications, including financial assistance programs that help alleviate treatment costs for patients.
3. Collaboration with Healthcare Providers: The company actively engages with healthcare professionals to improve understanding and treatment of rare diseases, sharing best practices in patient management.
4. Educational Initiatives: Alexion runs awareness campaigns and educational programs for healthcare providers and patients to underscore the importance of early diagnosis and treatment intervention in rare diseases.
Conclusion
In summary, Alexion Pharmaceuticals Inc. stands as a committed entity in the field of biopharmaceuticals, exclusively leveraging its expertise to deliver life-changing therapies for patients facing severe and ultra-rare disorders. Through an integrated approach that includes innovative product development, extensive research, and dedicated patient support services, Alexion is at the forefront of addressing the unique challenges posed by these complex health issues. The companys ongoing commitment to scientific advancement and patient care solidifies its position as a leader in this specialized domain.
Alexion Pharmaceuticals Inc. is a global biopharmaceutical company that focuses on developing and delivering innovative therapies for patients experiencing severe and ultra-rare disorders. Operating as a singular business segment, Alexion centers its efforts on providing specialized solutions tailored to meet the complex healthcare needs of this specific population. This targeted strategy streamlines decision-making, optimizes resource allocation, and fosters cross-functional collaboration across various operational pillars. Below is a detailed examination of the various segments, products, and services offered by Alexion Pharmaceuticals.
Business Segment Overview
Alexions strategic focus on the innovation, development, and commercialization of therapies allows it to operate without diversifying into less specialized areas. This concentrated operational model is designed to create a patient-first approach that prioritizes the unique and complex needs of individuals with severe illnesses. By concentrating its resources on specific diseases, Alexion enhances its ability to address unmet medical needs effectively.
Therapeutic Areas
Alexion Pharmaceuticals primarily concentrates its research and development activities in the following key therapeutic areas:
1. Hematology: This segment addresses a variety of blood disorders. Notable conditions include:
- Paroxysmal Nocturnal Hemoglobinuria (PNH): A rare and life-threatening blood disorder characterized by the destruction of red blood cells, leading to severe anemia.
- Complement-mediated Hemolytic Anemias: Conditions where the bodys immune system destroys red blood cells.
2. Neurology: Alexion is committed to addressing life-altering neurological disorders. A primary focus is:
- Neuromyelitis Optica Spectrum Disorder (NMOSD): An autoimmune condition that causes inflammation of the spinal cord and optic nerve.
3. Immunology: This area focuses on developing treatments that modulate the immune response, specifically for:
- Autoimmune Disorders: Conditions where the immune system erroneously attacks healthy cells.
4. Rare Genetic Diseases: Alexion targets various genetic disorders that require specialized treatment, often caused by mutations that severely impact health, including:
- Genetic metabolic disorders and other inherited conditions.
Key Products
Alexion Pharmaceuticals boasts a product portfolio largely characterized by monoclonal antibodies and complement inhibitors. Notable products include:
1. Soliris (eculizumab):
- This was the first drug approved for the inhibition of the complement protein C5. It is pivotal in treating PNH and atypical hemolytic uremic syndrome (aHUS), preventing complement-mediated damage to red blood cells and important organs.
2. Ultomiris (ravulizumab-cwvz):
- An innovative, longer-acting C5 inhibitor that provides treatment for PNH and aHUS with the advantage of requiring less frequent dosing compared to Soliris. Its pharmacokinetic profile offers enhanced patient convenience.
3. Strensiq (asfotase alfa):
- This enzyme replacement therapy is targeted at patients with hypophosphatasia, a rare genetic disorder that affects bone metabolism by providing the essential alkaline phosphatase enzyme that is lacking in these patients.
4. Kanuma (sebelipase alfa):
- Indicated for lysosomal acid lipase deficiency (LAL-D), this replacement therapy mitigates the severe health impacts associated with this genetic disorder.
Research and Development
Alexion Pharmaceuticals prioritizes extensive research and development efforts:
- Innovation: The company is heavily invested in discovering groundbreaking therapies for ultra-rare diseases, often targeting areas with minimal existing treatment options.
- Clinical Trials: Alexion conducts rigorous clinical trials that evaluate the safety and efficacy of its investigational therapies. These trials often involve collaborations with a global network of healthcare professionals, patients, and academic institutions.
- Pipeline Development: The company maintains a robust pipeline of investigational drugs aimed at meeting the needs of patients with severe and ultra-rare disorders, particularly focusing on complement inhibition and genetic conditions.
Patient-Centric Services
Alexion Pharmaceuticals features a suite of patient-centered services designed to support individuals receiving its therapies:
1. Patient Support Programs: These initiatives facilitate patient navigation through treatment protocols, providing essential educational resources alongside emotional and psychological support.
2. Access Solutions: Alexion implements various strategies to enhance patient access to its medications, including financial assistance programs that help alleviate treatment costs for patients.
3. Collaboration with Healthcare Providers: The company actively engages with healthcare professionals to improve understanding and treatment of rare diseases, sharing best practices in patient management.
4. Educational Initiatives: Alexion runs awareness campaigns and educational programs for healthcare providers and patients to underscore the importance of early diagnosis and treatment intervention in rare diseases.
Conclusion
In summary, Alexion Pharmaceuticals Inc. stands as a committed entity in the field of biopharmaceuticals, exclusively leveraging its expertise to deliver life-changing therapies for patients facing severe and ultra-rare disorders. Through an integrated approach that includes innovative product development, extensive research, and dedicated patient support services, Alexion is at the forefront of addressing the unique challenges posed by these complex health issues. The companys ongoing commitment to scientific advancement and patient care solidifies its position as a leader in this specialized domain.